PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30159225-1 2018 Objectives: The CYP2B6 is one of the most polymorphic CYP genes in humans that has the potential to modify the pharmacological and toxicological responses to clinically important drugs such as antimalarial artemisinin and its derivatives. artemisinin 206-217 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 16-22 28737446-10 2018 The fm, CYP2B6 values for artemisinin, bupropion, clopidogrel, ketamine, selegiline, sertraline and ticlopidine were 0.46, 0.17, 0.15, 0.60, 0.51, 0.66 and 0.77, respectively, in HLM determined by chemical inhibition method in the presence of BSA (0.5% w/v). artemisinin 26-37 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 8-14 28737446-9 2018 The fm, CYP2B6 values for artemisinin, bupropion, clopidogrel, ketamine, selegiline, sertraline and ticlopidine were 0.24, 0.28, 0.15, 0.45, 0.46, 0.42 and 0.54, respectively, in HLM determined by chemical inhibition method. artemisinin 26-37 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 8-14 25760540-1 2015 Repeated pretreatment with the antimalarial drug artemisinin (QHS) could lead to reduced exposure to the parent drug, which is mainly mediated by auto-induction of CYP2B6 activity. artemisinin 49-60 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 164-170 22679214-4 2012 To better understand the autoinduction and metabolic drug-drug interactions (DDIs), we evaluated the P450s (particularly CYP2B6 and CYP3A4) inhibited or induced by two artemisinin drugs, Qing-hao-su (QHS) and dihydroartemisinin (DHA) using human liver microsome, recombinant P450 enzymes, and primary human hepatocytes. artemisinin 168-179 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 121-127 23467454-3 2013 Drugs metabolized mainly by CYP2B6 include artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine, and methadone. artemisinin 43-54 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 22679214-4 2012 To better understand the autoinduction and metabolic drug-drug interactions (DDIs), we evaluated the P450s (particularly CYP2B6 and CYP3A4) inhibited or induced by two artemisinin drugs, Qing-hao-su (QHS) and dihydroartemisinin (DHA) using human liver microsome, recombinant P450 enzymes, and primary human hepatocytes. artemisinin 168-179 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 101-105 19562679-0 2009 Artemisinin--a possible CYP2B6 probe substrate? artemisinin 0-11 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 24-30 23506555-0 2012 The evaluation of CYP2B6 inhibition by artemisinin antimalarials in recombinant enzymes and human liver microsomes. artemisinin 39-50 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 18-24 23506555-2 2012 Some artemisinin compounds and anti-retroviral drugs have been shown to be metabolized by CYP2B6. artemisinin 5-16 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 90-96 23506555-4 2012 This study aimed to investigate whether artemisinin compounds inhibit CYP2B6 activity in vitro using recombinant CYP2B6 (rCYP2B6) and human liver microsomes (HLM). artemisinin 40-51 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 70-76 23506555-4 2012 This study aimed to investigate whether artemisinin compounds inhibit CYP2B6 activity in vitro using recombinant CYP2B6 (rCYP2B6) and human liver microsomes (HLM). artemisinin 40-51 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 113-119 23506555-7 2012 Artemisinin and artemether were shown to inhibit CYP2B6 in vitro through a partial mixed type of inhibition, while dihydroartemisinin did not inhibit the enzymatic activity. artemisinin 0-11 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 49-55 19702527-4 2009 CYP2B6 can metabolise approximately 8% of clinically used drugs (n > 60), including cyclophosphamide, ifosfamide, tamoxifen, ketamine, artemisinin, nevirapine, efavirenz, bupropion, sibutramine, and propofol. artemisinin 138-149 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 19562679-3 2009 Correlations between the metabolic rate constant for artemisinin and the other CYP2B6 substrates were examined. artemisinin 53-64 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 79-85 19562679-8 2009 CONCLUSIONS: The rate of in vitro metabolism of artemisinin was correlated significantly to that of bupropion, propofol and efavirenz, suggesting artemisinin to be a potential alternative marker to assess CYP2B6 activity. artemisinin 48-59 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 205-211 19562679-9 2009 Further studies characterizing the metabolic fate of artemisinin are needed in order to evaluate its utility as an in vitro and in vivo CYP2B6 probe substrate, since CYP2B6 might not be the only CYP isoform involved in the depletion of artemisinin. artemisinin 53-64 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 136-142 19562679-9 2009 Further studies characterizing the metabolic fate of artemisinin are needed in order to evaluate its utility as an in vitro and in vivo CYP2B6 probe substrate, since CYP2B6 might not be the only CYP isoform involved in the depletion of artemisinin. artemisinin 53-64 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 166-172 18350255-0 2008 A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. artemisinin 75-86 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 32-38 18350255-7 2008 In conclusion, all studied artemisinin derivatives induced CYP2B6. artemisinin 27-38 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 59-65 18350255-1 2008 The study aim was to assess the inductive properties of artemisinin antimalarials using mephenytoin as a probe for CYP2B6 and CYP2C19 enzymatic activity. artemisinin 56-67 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 115-121 18350255-5 2008 The production rate of CYP2B6 was increased 79.7% by artemisinin, 61.5% by arteether, 76.1% by artemether, 19.9% by dihydroartemisinin and 16.9% by artesunate. artemisinin 53-64 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 23-29 16506047-1 2006 OBJECTIVE: Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of artemisinin drugs, a novel series of antimalarials. artemisinin 73-84 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 11-30 16506047-1 2006 OBJECTIVE: Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of artemisinin drugs, a novel series of antimalarials. artemisinin 73-84 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 32-38 12844133-0 2003 Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. artemisinin 0-11 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 54-73 12844133-1 2003 AIM: Our goal was to investigate whether artemisinin autoinduction is caused by an increase in cytochrome P450 (CYP) 2B6 or CYP2C9 activities, we evaluated the effects of multiple-dose artemisinin administration on S-mephenytoin N-demethylation in healthy subjects. artemisinin 41-52 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 95-120 12844133-9 2003 CONCLUSIONS: These results indicate that artemisinin induces the N-demethylation of S-mephenytoin probably by an increased capacity of CYP2B6. artemisinin 41-52 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 135-141 12844133-10 2003 The autoinduction phenomenon of artemisinin may, therefore, be attributed, at least in part, to induction of CYP2B6, because this is the isozyme primarily involved in its metabolism. artemisinin 32-43 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 109-115 10583023-5 1999 RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model. artemisinin 38-49 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 10583023-5 1999 RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model. artemisinin 38-49 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 122-128 10583023-5 1999 RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model. artemisinin 38-49 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 122-128 10583023-5 1999 RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model. artemisinin 95-106 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 10583023-5 1999 RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model. artemisinin 95-106 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 122-128 10583023-5 1999 RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model. artemisinin 95-106 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 122-128 10583023-5 1999 RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model. artemisinin 95-106 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 10583023-5 1999 RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model. artemisinin 95-106 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 122-128 10583023-5 1999 RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model. artemisinin 95-106 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 122-128 33599403-2 2021 Drugs metabolized mainly by CYP2B6 include artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine, and methadone. artemisinin 43-54 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 28-34 17115150-11 2007 It is important to determine if these differences, along with previously reported differences in cytochrome P450 2B6 allele frequencies, are associated with altered metabolism/effectiveness of artemisinin drugs. artemisinin 193-204 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 97-116 15761118-6 2005 By combining in vitro transfection methods and quantitative analyses of gene expression in cell lines and primary human hepatocytes, we here show that artemisinin drugs activate human PXR as well as human and mouse CAR and induce the expression of CYP2B6, CYP3A4, and MDR1 in primary human hepatocytes and in the human intestinal cell line LS174T. artemisinin 151-162 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 248-254 12619052-3 2003 The metabolic fate of (14)C-artemisinin in microsomes from human B-lymphoblastoid cell lines transformed with CYP2A6, CYP2B6 and CYP3A4 was also investigated. artemisinin 28-39 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 118-124 11432537-10 2001 CYP2B6 and CYP3A4 are involved in the metabolism of artemisinin and derivatives, but further studies may reveal involvement of more enzymes. artemisinin 52-63 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 0-6 10583023-10 1999 The rate of artemisinin metabolism in recombinant CYP2A6 was 15% of that for recombinant CYP2B6. artemisinin 12-23 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 89-95 10583023-12 1999 CONCLUSIONS: Artemisinin metabolism in human liver microsomes is mediated primarily by CYP2B6 with probable secondary contribution of CYP3A4 in individuals with low CYP2B6 expression. artemisinin 13-24 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 87-93 10583023-12 1999 CONCLUSIONS: Artemisinin metabolism in human liver microsomes is mediated primarily by CYP2B6 with probable secondary contribution of CYP3A4 in individuals with low CYP2B6 expression. artemisinin 13-24 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 165-171 33875422-10 2021 Between one in three and one in six individuals harbored reduced activity alleles of CYP2A6, CYP2B6, CYP2D6 and CYP2C8 with important implications for artemisinin, chloroquine and amodiaquine therapy. artemisinin 151-162 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 93-99